Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 inhibitor …
Suffering two separate clinical trial blows, Bristol Myers Squibb and a collaboration between Merck KGaA and Pfizer learned the hard way that head and neck …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
